晚发型Leber遗传性视神经病变:大型意大利队列的疾病触发因素与预后因素
该回顾性队列研究纳入77例晚发型LHON患者(发病年龄≥40岁),分析其临床遗传特征、触发因素及视力恢复相关因素。结果显示m.11778G>A突变占62.7%,吸烟史占58.2%,总体视力恢复率38.8%;探索性分析提示艾地苯醌≥900 mg/天及J或T线粒体单倍群与更高恢复概率相关。
要点
- 晚发型LHON中m.11778G>A突变占62.7%,男女比1.48:1。
- 吸烟史见于58.2%患者,85.2%女性为绝经后。
- 总体视力恢复率38.8%,艾地苯醌≥900 mg/天和J或T单倍群与恢复相关。
核心结论
- 晚发型LHON是临床相关亚型,环境及激素因素可能促发疾病转化。
- 回顾性队列中高剂量艾地苯醌与更高视力恢复概率相关,尤其J或T单倍群患者。
- 上述探索性发现属假设生成,需前瞻性研究证实。
研究设计与样本
- 回顾性队列研究,从398例意大利LHON患者中识别77例晚发型(发病≥40岁)。
- 对67例进行完整临床和遗传分析,以562名健康个体作线粒体单倍群比较的内对照组。
- 采用探索性CHAID分析生成假设决策树模型。
主要发现
- m.11778G>A突变占62.7%,男女比1.48:1,低于经典LHON。
- 吸烟史占58.2%,85.2%女性为绝经后,原发性开角型青光眼占6%,LHON“plus”表型占7.5%。
- 总体视力恢复率38.8%。
- CHAID分析提示艾地苯醌≥900 mg/天及J或T线粒体单倍群与更高视力恢复概率相关。
关键数值与推荐
- 视力恢复定义为最佳矫正视力改善至少0.3 logMAR或从表外转为表内视力。
- 晚发型LHON定义为发病年龄≥40岁。
- 艾地苯醌剂量≥900 mg/天与更高恢复概率相关。
临床怎么用
- 对晚发型LHON患者应评估吸烟史、绝经状态及系统性共病等可能触发因素。
- 遗传检测应涵盖原发mtDNA突变、线粒体单倍群及NQO1多态性。
- 高剂量艾地苯醌和J或T单倍群可作为预后咨询的探索性参考。
局限性
- 回顾性设计,仅67例完成完整临床和遗传分析。
- CHAID分析为探索性,结果属假设生成。
- 需前瞻性研究确认预后因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To characterize the clinical and genetic features, investigate disease triggers, and explore factors associated with visual recovery in late-onset Leber hereditary optic neuropathy (LHON). DESIGN: Retrospective cohort study. PARTICIPANTS: Seventy-seven patients with late-onset LHON (onset ≥40 years of age) were identified from a larger cohort of 398 Italian patients with LHON. Full clinical and genetic analyses were performed on 67 of these patients, whereas an internal control group of 562 healthy individuals was used for mitochondrial haplogroup comparisons. METHODS: Patient medical records were retrospectively reviewed to assess demographics, environmental exposures (smoking history), hormonal status (menopause and hormonal therapy), systemic comorbidities, and idebenone treatment data. Genetic testing evaluated primary mitochondrial DNA (mtDNA) mutations, mitochondrial haplogroups, and NAD(P)H quinone dehydrogenase 1 (NQO1) polymorphisms. Statistical relationships were investigated using an exploratory chi-square automatic interaction detection (CHAID) analysis to generate hypothesis-generating decision tree models. MAIN OUTCOME MEASURES: The primary outcome measures were the identification of precipitating factors (disease triggers) for LHON conversion and the rate of visual recovery, which was defined as an improvement of at least 0.3 logarithm of the minimum angle of resolution or a change from off-chart to on-chart visual acuity. RESULTS: The m.11778G>A variant was the predominant mtDNA mutation (62.7%), and the male-to-female ratio was lower than in canonical LHON (1.48:1). Smoking history was present in 58.2% of patients, and 85.2% of women were postmenopausal. Other relevant factors included primary open-angle glaucoma (6%) and the LHON "plus" phenotype (7.5%). The overall visual recovery rate was 38.8%. Exploratory CHAID analysis suggested that idebenone treatment at a dosage of ≥900 mg/day and the presence of a J or T mitochondrial haplogroup were associated with a higher probability of visual recovery. CONCLUSIONS: Late-onset LHON represents a clinically relevant subset in which environmental and hormonal factors may contribute to disease conversion. In this retrospective cohort, high-dose idebenone treatment was associated with a higher probability of visual recovery, particularly among patients with a J or T haplogroup background. These exploratory findings should be considered hypothesis generating and warrant confirmation in prospective studies. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Battista M, Carbonelli M, Brotto L, et al. Late-Onset Leber Hereditary Optic Neuropathy: Disease Triggers and Prognostic Factors in a Large Italian Cohort. Ophthalmology. 2026. PMID: 42612876. doi:10.1016/j.ophtha.2026.08.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。